Survival rates

If you've been diagnosed with hepatocellular carcinoma, one of the first things you might wonder about is the survival rate for this type of cancer. Survival rates come from following a large group of people with the same diagnosis for a set amount of time. Cancer survival rates often state what percentage of that group is still living five years after a cancer diagnosis.

The U.S. National Cancer Institute gives survival rates for all liver cancers together. These rates include people with hepatocellular carcinoma and also those with intrahepatic cholangiocarcinoma, which is cancer that happens in the bile ducts inside the liver. Using this data, the survival rates are given by the extent of the cancer.

  • Localized liver cancer, which means the cancer is only in the liver, has a five-year survival rate of about 38%. This means that for every 100 people with this diagnosis, about 38 would be expected to be living five years after diagnosis.
  • Regional liver cancer, which means the cancer may have spread to nearby lymph nodes, has a five-year survival rate of about 13%.
  • Distant liver cancer, which means the cancer has spread to other parts of the body, is also called metastatic liver cancer. The five-year survival rate is about 4%.

These numbers include people with different kinds of liver cancer and different treatments, including some who didn't have treatment. Keep in mind that these numbers are based on people who were diagnosed more than five years ago. They may not have had access to the latest treatments.

Hepatocellular carcinoma survival rates can give you an idea of the prognosis for people in your situation. But survival rates can't say whether you will be cured. For the clearest and most complete picture of your outlook, talk about it with your healthcare team. Your care team understands your overall health and can give a more personalized prognosis.

There are many factors that a healthcare team thinks about when deciding on a prognosis, including:

  • The size of the cancer. A small cancer or a few small areas of cancer have a better prognosis, as they may be easier to remove with surgery.
  • How much of the liver is affected. If cancer affects a lot of the liver, this gives a worse prognosis.
  • How well the liver is working. Having good liver function gives a better prognosis.

A small hepatocellular carcinoma that can be completely removed with surgery has a good chance for a cure, especially if the remaining liver is healthy. In this situation, the five-year survival rate can be as high as 90%. For those who also have liver disease, liver transplant also can cure the cancer. Studies have found five-year survival rates after transplant of 75% or higher.

Liver cancer tends to grow quickly. Many people may not be healthy enough for surgery or may have cancer that can't be removed with surgery. In those situations, the chance of surviving at least five years is lower.

The Barcelona Clinic Liver Cancer Staging System, which is a common system for staging hepatocellular carcinoma, includes general estimates of life expectancy for people with this cancer. These life expectancy numbers give the healthcare team an idea of how long a person may be expected to live after treatment based on the stage of the cancer.

  • Stage 0 has a life expectancy of more than five years.
  • Stage A has a life expectancy of more than five years.
  • Stage B has a life expectancy of more than five years when liver transplant is used. When transplant isn't an option, localized therapies have a life expectancy of more than 2.5 years. Treatment with medicines has a life expectancy of more than two years.
  • Stage C has a life expectancy of more than two years.
  • Stage D has a life expectancy of 3 months.
Sept. 11, 2025

Living with hepatocellular carcinoma (HCC)?

Connect with others like you for support and answers to your questions in the Transplants support group on Mayo Clinic Connect, a patient community.

Transplants Discussions

lmctif
Liver transplant - Let's support each other

1688 Replies Fri, Aug 08, 2025

Curses
MELD score less than 15?

12 Replies Tue, Jul 15, 2025

See more discussions
  1. Elsevier Point of Care. Clinical Overview: Hepatocellular carcinoma. https://www.clinicalkey.com. Accessed Nov. 18, 2024.
  2. Hepatocellular carcinoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514. Accessed July 25, 2025.
  3. Primary liver cancer treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq. Accessed Nov. 18, 2024.
  4. Liver (hepatocellular) cancer prevention (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq. Accessed Nov. 18, 2024.
  5. Schwartz JM, et al. Clinical features and diagnosis of hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed July 30, 2025.
  6. Abdalla EK, et al. Overview of treatment approaches for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 5, 2025.
  7. Stuart KE. Systemic treatment for advanced hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024.
  8. Schwartz JM, et al. Epidemiology and risk factors for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024.
  9. Curley SA, et al. Surgical resection of hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024.
  10. Tsoulfas G, et al. Liver transplantation for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 5, 2025.
  11. Palliative care. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454. Accessed Nov. 18, 2024.
  12. Hepatitis C prevention and control. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis-c/prevention/index.html. Accessed Nov. 18, 2024.
  13. 2020-2025 Dietary Guidelines for Americans. U.S. Department of Health and Human Services and U.S. Department of Agriculture. https://www.dietaryguidelines.gov. Accessed Nov. 18, 2024.
  14. TACE. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/chemoembol. Accessed Nov. 18, 2024.
  15. Radioembolization (Y90). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/radioembol. Accessed Nov. 18, 2024.
  16. Thermal ablation for tumor treatment. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/thermal-ablation-therapy. Accessed Nov. 18, 2024.
  17. Liver cancer. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/liver-cancer/about/index.html. Accessed Nov. 18, 2024.
  18. Hepatitis B vaccine. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis-b/vaccination/index.html. Accessed Feb. 7, 2025.
  19. Feldman M, et al., eds. Hepatic tumors and cysts. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 11th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed July 25, 2025.
  20. DeVita VT Jr, et al., eds. Cancer of the liver. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. ProQuest Ebook Central. Wolters Kluwer; 2023. Accessed Feb. 11, 2025.
  21. Suriawinata A. Pathology of malignant liver tumors. https://www.uptodate.com/contents/search. Accessed July 25, 2025.
  22. Kalman RS, et al. Epidemiology, clinical manifestations, diagnosis and treatment of fibrolamellar carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 6, 2025.
  23. Ferri FF. Jaundice in the adult patient. In: Ferri's Clinical Advisor 2026. Elsevier; 2026. https://www.clinicalkey.com. Accessed Aug. 1, 2025.
  24. McPherson RA, et al., eds. Evaluation of liver function. In: Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 1, 2025.
  25. Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology. 2022; doi:10.1016/j.jhep.2021.11.018.
  26. Cancer stat facts: Liver and intrahepatic bile duct cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/livibd.html. Accessed Aug. 5, 2025.
  27. Tecentriq (prescribing information). Genentech; 2024. https://www.tecentriq.com. Accessed Aug. 5, 2025.
  28. Lenvima (prescribing information). Eisai; 2025. https://www.lenvima.com. Accessed Aug. 5, 2025.
  29. Health Education & Content Services. Liver cancer: Hepatocellular carcinoma. Mayo Clinic; 2023.
  30. Nimmagadda R. Allscripts EPSi. Mayo Clinic. Feb. 26, 2025.
  31. Liver SPOREs. National Cancer Institute. https://dctd.cancer.gov/research/spores/focus-area/liver. Accessed Aug. 6, 2025.
  32. Santol J, et al. An APRI+ALBI-based multivariable model as preoperative predictor for posthepatectomy liver failure. Annals of Surgery. 2023; doi:10.1097/SLA.0000000000006127.
  33. Starlinger P, et al. Combined APRI/ALBI score to predict mortality after hepatic resection. BJS Open. 2021; doi:10.1093/bjsopen/zraa043.
  34. Kern AE, et al. MicroRNA based prediction of posthepatectomy liver failure and mortality outperforms established markers of preoperative risk assessment. Annals of Surgical Oncology. 2025; doi:10.1245/s10434-025-17528-x.
  35. Dong Y, et al. Preoperative von Willebrand factor is an independent predictive biomarker for posthepatectomy liver failure — A multivariable model with APRI+ALBI. Liver Transplantation. 2025; doi:10.1097/LVT.0000000000000676.